Compliance with antimicrobials de-escalation in septic patients and mortality rates: an old subject revisited

Jamal Wadi AlRamahi1, OmranAbu Khalaf2, Lamya Abu Shanab Pharm3, Mohammad Obaidat Pharm4, Maha Al Hasan2, Mohammed Mhanna5, Maha Hashim Abdulghani5

Abstract

Background: To compare the recent de-escalations rates with a six-year earlier study, and mortality associated with de-escalation.

Methods: A prospective multicenter study including septic patients, all were on broad-spectrum antimicrobials (BSA). Excluded from the study patients on antimicrobial prophylaxis, and patients without a microbiological diagnosis, or bacteria were solely BSA-susceptible. The study team made recommendations for antimicrobials de-escalation to the treating physician(s) must an opportunity loomed.

Results: 182 patients were available for analysis. De-escalation was achieved in 43 (24%) patients. The clinical diagnoses, comorbidities, commonly used antimicrobials, the microbiological diagnoses were not different between the two groups (patients with and without de-escalation). Logistic regression analysis showed no correlation between bacterial species and de-escalation (Nagelkerke R2 = 0.076). Relapsing sepsis and reinfection were not different (P > 0.05). The in-hospital mortality rates for the de-escalated patients were lower (P = 0.015) but not on day 30 (P = 0.354). The length of the ICU stay and ward stay were not different (P >0.05), but more de-escalated patients were discharged home from the ICU (P = 0.034), however, patients without de-escalation were discharged more from the ward (P = 0.002).

Conclusion: De-escalation rates increased within six years from 6.7%-24% (P = 0.000), with added benefits of shorter ICU stay and less in-hospital mortality

© Under License of Creative Commons Attribution 3.0 License | This article is available at: www.iajaa.org / www.medbrary.com
Introduction

De-escalation is one of the paradigms of a multifaceted antimicrobials stewardship (AMS) that avoids unnecessary use of the broad-spectrum antimicrobials (BSA) and their extended duration, it is mostly based on a microbiological diagnosis and susceptibility [1-4]. The old dictum “hit hard and hit fast” is a principle in treating patients with severe sepsis, it focuses on treating patients appropriately and early [5, 6], this would help improving outcomes without undue delay at a time before a microbiological diagnosis is available [7]. With the rapid evolution of the diagnostic methods with rapid bacterial identification and susceptibility patterns, de-escalation as a concept must be a common practice, especially it is known to a meliorate the BSA sustained pressure upon bacteria, and cause less resistance [8], and adapting to a culture-driven antimicrobial therapy became evidently beneficial; the benefits of de-escalation are being frequently cited for lowering treatment costs, reducing the chances of inducing resistant among bacterial strains, reducing antimicrobials’ toxicity and collateral damage of BSA [9-12], none the less many physicians do not feel comfortable with de-escalation: “why change, it works” [13-14]. Earlier in Amman - Jordan, we published a study that showed poor compliance with de-escalation. Now, we aim to re-evaluate the rates of the antimicrobials de-escalation in the same hospitals and almost the same staff after the accreditation by the Joint commission International (JCI) whom surveillance includes elements of a working stewardship program [15-16]. We plan to test the hypothesis that JCI-driven recommendations convince the hospitals and the physicians in adopting the practice of de-escalation for being an important element of antimicrobial stewardship leading to a better patients’ care, and help in lowering resistance rates, cost and mortality. Although there is no adequate information from controlled trials so far, but observational ones revealing a better outcome in the de-escalated patients [17-20]. Our study aims to respond to skepticism, and if prove useful, it may encourage the practicing physician to de-escalate to a focused antimicrobial therapy when an opportunity arises.

Materials and Methods

Setting

A multicenter prospective study held in Amman – Jordan, between December 2014 to March 2019. It was conducted in three private hospitals; two teaching; The Specialty (Al Takhassusi) and Jordan Hospital and one community service hospital; Al Khalidi, with a total of 650 beds and 52 ICU beds. The three hospitals have no antimicrobials restriction policy. The internal review boards of each hospital approved the study. Daily charts review on antimicrobial prescription, changes in prescription and progress of patients (see inclusion criteria) were monitored. Each study team in the teaching hospitals included a clinical pharmacist and a medical resident, and clinical pharmacists in the community hospital. Follow up on the microbiological data, diagnosis accuracy according to CDC published criteria for nosocomial infections and the microbiologically documented diagnoses for admitted patients with community-associated infections were revised. The clinical pharmacist and/or the medical residents suggested de-escalation to the attending physician when there was an opportunity, the attending physician is the responsible prescriber for accepting or rejecting the de-escalation or escalating the regimen. Thirty days after the patients discharge, they were followed up by phone calls for mortality.

Inclusions and exclusion criteria

Patients were included if they were diagnosed to have documented sepsis, or septic shock associated with community-acquired pneumonia (CAP),
ventilator-associated pneumonia (VAP), catheter-associated urinary tract infections (CAUTI), severe urinary tract infections (UTI), central line-associated blood stream infection (CLABSI), bacteremia of undefined source and blood cultures were available, skin and skin structure infection (SSTI) intra-abdominal infection (IAI) and meningitis, for which BSA agents as mono-therapy or in combination were prescribed [21]. Failure to de-escalate was considered for patients when a bacterial culture and its susceptibility were known, and the causative bacteria could be treated with a focused narrow-spectrum antimicrobial, but the treating physician continued using the initial or an alternative BSA monotherapy or in combination despite the clinical pharmacist advice. Excluded patients those who were not started on BSA agents, were on antimicrobial prophylaxis, there was no clear indication for the use of BSA agents, and all septic patients whom do not have a microbiological diagnosis. The following available agents were considered BSA agents: carbapenems, β-lactam β-lactamase inhibitors, glycylcyclines, respiratory quinolones and the parenteral third and fourth generations’ cephalosporins, and combination antimicrobials therapies prescribed in treating seriously sick patients and intended to provide BSA coverage with or without vancomycin or teicoplanin.

**Outcome measures**

The primary outcome measure is to evaluate the difference in the rates of de-escalated patients from BSA to an appropriate narrow spectrum agent and comparing the rates with a previous study we published earlier in this regard [15]. And to estimate the mortality rates associated with de-escalation compared with patients without de-escalation. Secondary outcome measures were if physicians’ attitude were influenced by patients’ admission location, comorbidities, clinical diagnosis and microbiological diagnosis.

**Statistical analysis**

Rates of the antimicrobials de-escalation were calculated, t-student test was used to estimate the difference between the means and proportions. Secondary outcomes were analyzed by Fischer’s exact test or $\chi^2$ to demonstrate if there were differences among different estimators. Two-sided $P \leq 0.05$ is considered significant. Logistic regression analysis was used for border line P-value to support relation between the tested variable and the de-escalation. Data were analyzed using SPSS (IBM corporation, version 22, 2018).

**Results**

There were 182 patients available for analysis. De-escalation was achieved in 43(24%) patients. Males were 109 (59%), there was no significant gender difference between both de-escalation and without de-escalation groups ($P = 0.375$). The clinical diagnoses and comorbidities were not significantly different between the two groups, as well as the commonly used antimicrobials ($P > 0.05$). The microbiological diagnoses showed no significant difference ($P = 0.05$), logistic regression analysis showed no correlation between bacterial species and the de-escalation (Nagelkerke pseudo-R2 = 0.076). Relapsing sepsis and reinfection in both groups were few in numbers and no significant differences were detected ($P > 0.05$), though all the few relapsed cases and most cases in the reinfection were in patients without de-escalated (Table 1).

**Table 1. Demography and characteristics of patients in the de-escalation study.**

| Characteristic          | De-escalated | Not De-escalated | P-value |
|-------------------------|--------------|------------------|---------|
| Number of Patients      | N (182)      | N (%)            |         |
| Age mean* (Years)       | 61.66        | 63.45            | 0.559   |

© Under License of Creative Commons Attribution 3.0 License
The in-hospital mortality rates for the de-escalated patients were significantly lower than those without de-escalation ($P = 0.029$), but there was no mortality difference on day 30 ($P = 0.503$) (Figure A). Patients who were escalated have higher in-hospital mortality than those without de-escalation ($P = 0.000$), and tendency towards higher mortality on day 30 ($P = 0.051$) (Figure B). The length of the ICU stay and the ward stay were

### Table 1: Characteristics of the Study Patients

| Characteristic                  | De-escalated | Not De-escalated | P-value |
|--------------------------------|--------------|------------------|---------|
| **Gender**                     |              |                  |         |
| Males                          | 23           | 86               | 0.375   |
| Females                        | 20           | 53               |         |
| **Clinical Diagnosis**         |              |                  |         |
| Bacteremia                     | 12           | 38               |         |
| CAP                            | 3            | 14               |         |
| Sepsis/undefined               | 7            | 37               | 0.464   |
| UTI                            | 15           | 39               |         |
| Others                         | 6            | 11               |         |
| **Comorbidities**              |              |                  | 0.739   |
| DM                             | 26           | 96               |         |
| COPD/Chronic lung disease      | 3            | 24               |         |
| Skin disease                   | 1            | 7                |         |
| Hematological malignancy       | 8            | 9                |         |
| Solid Malignancy               | 5            | 18               |         |
| Immunosuppressive states       | 10           | 32               |         |
| Others Comorbidities**         | 29           | 91               | 0.128   |
| **Microbiological diagnosis**  |              |                  |         |
| Enterobacteriaceae             | 23           | 51               | 0.05    |
| S. aureus                      | 7            | 25               |         |
| Lactose non fermenters         | 3            | 20               |         |
| Enterococci                    | 4            | 4                |         |
| N/A                            | 6            | 39               |         |
| **Commonly used antimicrobials**|             |                  |         |
| Carbapenems                    | 25           | 75               |         |
| Pipracillin/tazobactam         | 11           | 24               |         |
| Cephalosporines (3rd and 4th)  | 7            | 17               | $\geq 0.2$ |
| Tigecycline                    | 0            | 5                |         |
| Colistin                       | 0            | 1                |         |
| Glycopeptides                  | 7            | 29               |         |
| Quinolones                     | 1            | 33               | 0.001   |
| **Relapse**                    |              |                  |         |
| Clinical                       | 2            | 3                | $>0.3$  |
| Microbiological                | 0            | 2                |         |
| Microorganism                  | 0            | 1                |         |
| Site$^2$                       | 1            | 3                |         |
| **Reinfection**                |              |                  |         |
| Acinetobacter spp.             | 0            | 2                | 0.742   |
| Enterococci                    | 0            | 1                |         |
| Others                         | 0            | 1                |         |

*P-value was tested by ANOVA and was significant.

**P-value was tested by ANOVA and was significant.

1: By Fisher exact test, 2-sided.
2: 1 VAP in each arm, 1 undefined sepsis and 1 bacteremia.

---

**Figure A, B: In-hospital and 30-days mortality rates for patients.**

A) with and without de-escalation; B) for escalation and without escalation.

Patients. De-escalated number of patients = 42, and without de-escalation = 139. Escalated number of patients = 52 and without escalation = 130. Note that the 130 without escalation have included those with de-escalation = 43. P-value significance was tested by 2-sided Fisher’s exact test.
not significantly different (P > 0.05) between the two groups, but significantly more de-escalated patient were discharged home directly from the ICU (P = 0.034), however, in the ward the patients without de-escalation were discharge sooner (P = 0.002) (Table 2).

Table 2. The means of the length of stay in the ICU and the hospital ward for patients with de-escalation and without de-escalation.

| Characteristic                              | The mean of the days and the (number of patients) | P-Value |
|---------------------------------------------|---------------------------------------------------|---------|
|                                             | De-escalated                                      | Not De-escalated |
|                                             | N   | %    | N   | %    |         |
| Length of Stay (ICU)                        | 4.81| 42   | 5.7 | 137  | 0.584   |
| Length of Stay (ward)                       | 6.37| 42   | 4.93| 137  | 0.097   |
| Transferred from ward to ICU               | 1.83| 7    | 1.77| 32   | 0.383   |
| Discharged home from ward                  | 1.19| 34   | 1.46| 75   | 0.002   |
| Discharged home from ICU                   | 1.95| 2    | 1.82| 25   | 0.034   |

*: Two-sided student t-test for the mean length of stay in days

Discussion
The concept of de-escalation came into practice as BSA agents were found not devoid of flaws when used appropriately, not to mention the unjustified regimen, duration, dose and frequency of a therapeutic regimen, where CDI, MRSA, VRE, ESBL and CRE are becoming the major culprit of the wide “and indiscriminate” use of BSA agents [22-27]. The aim of this study was to evaluate the changing rates of de-escalation and the associated mortality, after the JCI enforcement on the antimicrobial stewardship. There was an improvement in the rates of de-escalation, it significantly soared from 6.7% to 24% (P = 0.000) in six years (2012 to 2018), though the absolute rise in number is a modest one, but it was almost quadrupled, this is an encouraging step to keep momentum for education, ward suggestions and administrations support in the pursuit of better antimicrobial utilization. Recorded rates for de-escalation in several countries of the world may reach 32.1%-51%, higher than our improved rates [28-30].

The in-hospital mortality was lower in the de-escalated patients (P = 0.029), the results of a previous work demonstrated that de-escalation in severe sepsis and septic shock was safe with a lower mortality [19, 31] even in culture negative septic patients with healthcare-associated pneumonia [32]. Escalating the antimicrobial therapy in a subset of patients had significantly higher in-hospital mortality (P = 0.000) and tendency towards higher mortality on day 30 (P = 0.051), possibly because the treating physicians were hesitant to de-escalate, on the contrary, antimicrobial treatment was escalated in the very sick patients, following the idea “more is better”. However, the addition of another antimicrobial did not alter the outcome of those subset of patients, and they had a higher mortality compared with patients without escalation, similar to was found earlier that escalation were associated with a higher mortality in non bacteremic patients with pneumonia, though it was confounded by a higher inappropriate therapy [33]. Notably, the length of ICU Stay and ward stay were not different for both groups (P > 0.05), but the hospital discharge were significantly better for patients with de-escalation from the ICU and from the medical ward at home (P < 0.05), this also
saves cost as always demonstrated [34]. Needless to stress on the fact that cost saving is of a paramount priority for resources-limited countries.

No differences were noted for transferring patients from the ward to the ICU between the two groups (P = 0.383), this highlights the safety of de-escalation, and the patients’ likelihood to become sicker and being transferred to the ICU is the same in both groups. Our study was not APACH II or SOFA score adjusted, however, comparisons of many confounders were not significantly different between the two groups (Table 1), this may contribute to some robustness of our results. A point to consider is that the data were not segregated into teaching versus not teaching hospital. Another point to consider is the Hawthorne phenomena effect; our study though it was observational, but it was monitored by residents and clinical pharmacist who suggested and observed and phoned the attending physicians for their prescribing practices, this may have added to the improved de-escalation rates [35], this would invite the health care administrators to seriously implement methods and procedures in this regard as education alone may not have been enough. In conclusion, the de-escalation rates improved significantly over time with added benefits of shorter ICU stay, cost saving and less in-hospital mortality. Furthermore, escalating antimicrobial therapy was not associated with a better outcome.

Acknowledgements

We appreciate the help provided by Ali Ayesh MD and Mohammad Khalil from Jordan hospital. Dania Al Momani PharmD, Nedal Al Mahamid PharmD and Mustafa Alaskar PharmD from Al Khalidi Hospital.

References

1. Thomas M. Hooton et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Guidelines for Developing an Institutional Program to Enhance Antimicrobial Stewardship. Clin Infect Dis 2007; 44:159-77.
2. Reham Kaki, Marion Elligsen, Sandra Walker, Andrew Simor, Lesley Palmay and Nick Daneman. Impact of antimicrobial stewardship in critical care: a systematic review. J Antimicrob Chemother 2011; 66: 1223-1230.
3. Drew RH. Antimicrobial stewardship programs: how to start and steer a successful program. J Manag Care Pharm 2009;15(2):S18-23.
4. Dimple Patel, Wendy Lawson and B Joseph Guglielmo. Review, Antimicrobial stewardship programs: interventions and associated outcomes. Expert Rev Anti Infect Ther 2008;6(2):209-222.
5. Ehrlich P. Chemotherapeutics: scientific principles, methods, and results. Address in pathology to 17th International Congress of Medicine. (London, 1913). Lancet 1913; 2:445-51
6. Leone, Marc; Bourgoin, Aurélie; Cambon, Sylvie; Dubuc, Myriam; Albanèse, Jacques; Martin, Claude. Empirical antimicrobial therapy of septic shock patients: Adequacy and impact on the outcome. Crit Care Med 2003;31(2):462-467.
7. John D. Dickinson, Marin H. Kollef. Early and Adequate Antibiotic Therapy in the Treatment of Severe Sepsis and Septic Shock. Curr Infect Dis Rep 2011 r;13(5): 399-405.
8. Marin H. Kollef. Broad-Spectrum Antimicrobials and the Treatment of Serious Bacterial Infections: Getting It Right Up Front. Clin Infect Dis 2008; 47:S3-13.
9. Timothy H. Delitt, Robert C. Owens, John E. McGowan, Jr., Dale N. Gerding, Robert A. Weinstein, John P. et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Guidelines for Developing an Institutional Program to Enhance Antimicrobial Stewardship. Clin Infect Dis 2007; 44:159-77.
10. Michael S. Niederman. Use of Broad-Spectrum Antimicrobials for the Treatment of Pneumonia in Seriously Ill Patients: Maximizing Clinical Outcomes and Minimizing Selection of Resistant Organisms. Clin Infect Dis 2006; 42:S72-81.
11. Johannes P Borde, Klaus Kaier, Michaela Steib-Bauert, Werner Vach, Annette Geibel-Zehender, Hansjörg et al. Feasibility and impact of an intensified antibiotic stewardship programme targeting cephalosporin and fluoroquinolone use in a tertiary care university medical center. BMC Infect Dis 2014; 14:201.
12. David L. Paterson. “Collateral Damage” from Cephalosporin or Quinolone Antibiotic Therapy. Clinical Infectious Diseases 2004; 38(Suppl 4):S341-5
13. P. G. Davey and C. Marwick. Appropriate vs. inappropriate antimicrobial therapy. Clin Microbiol Infect 2008; 14 (Suppl. 3): 15-21.
14. L Phee et al. De-escalation of antimicrobial therapy in Gram-negative sepsis: easier said than done? Critical Care 2011, 15(Suppl 1):P219.

15. Jamal Wadi, Sahar Al Shair, Waseem Abu Ashour, Mohammad Rabi, Haifa Petro, Amarni Romman, et al. Physicians compliance with antimicrobials’ de-escalation in intensive care units in Jordan. IAJAA 2013;2(1): 1-5. doi: 10.3823/725.

16. Jan J. De Waele. De-escalation after empirical meropenem treatment in the intensive care unit: Fiction or reality? J Crit Care 2010: 25 (4):641-646.

17. The Joint commission. Antimicrobial Stewardship. http://www.jointcommission.org/topics/antimicrobial_stewardship.aspx. Last accessed July 2019

18. Silva BN, Andriolo RB, Atallah AN, Salomão R. De-escalation of antimicrobial treatment for adults with sepsis, severe sepsis or septic shock. Cochrane Database of Systematic Reviews. 2010(12).

19. Garnacho-Montero J, Gutiérrez-Pizarra A, Escoresca-Ortega A, Corcia-Palomo Y, Fernández-Delgado E, Herrera-Melero I, et al. De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock. Int Care Med 2014;40(1):32-40.

20. Rello J, Vidal-Puig, Sandiumenge A, Rodriguez A, Gualis B, Boque C, et al. De-escalation therapy in ventilator-associated pneumonia. Crit Care Med 2004;32(11):2183-2190.

21. R. P. Dellinger, Mitchell M. Levy, Andrew Rhodes, DjillaliAnnane, Herwig Gerlach, Steven M. Opal, et al. The Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup. Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012. Intensive Care Med 2013; 39:165-228

22. Marin H. Kollef. Appropriate Empirical Antibacterial Therapy for Nosocomial Infections Getting it Right the First Time. Drugs 2003; 63 (20): 2157-2168.

23. Moir’a Joe’ IleTalpaert, GuduruGopasiRao, Ben Symons Cooper and Paul Wade. Impact of guidelines and enhanced antibiotic stewardship on reducing broad-spectrum antibiotic usage and its effect on incidence of Clostridium difficile infection. J Antimicrob Chemother 2011; 66: 2168-2174.

24. Mark H. Wilcox. The tide of antimicrobial resistance and selection. Int J Antimicrob Agents 2009;34; 53 S6 S10.

25. Simona Bratu, Steven Brooks, Sibte Burney, Sandeep Kochar, Jyoti Gupta, David Landman, and John Quale. Detection and Spread of Escherichia coli Possessing the Plasmid-Borne Carbapenemase KPC-2 in Brooklyn, New York. Clin Infect Dis 2007; 44:972-5.

26. Carl Urban, Patricia A. Bradford, Margareta Tuckman, Sorana Segal-Maurer, WehebWeheb, Louise Grenner, et al. Carbapenem-Resistant Escherichia coliHarboring Klebsiella pneumonia Carbapenemase b-Lactamases Associated with Long-Term Care Facilities. Clin Infect Dis 2008; 46:el27-30.

27. Kenneth M. Wener, VeredSchechner, Howard S. Gold, Sharon B. Wright, et al. Treatment with Fluoroquinolones or with β-Lactam β-Lactamase Inhibitor Combinations Is a Risk Factor for Isolation of Extended-Spectrum β-Lactamase-Producing Klebsiella Species in hospitalized Patients. Antimicrob Agents Chemother 2010; 54(5): 2010-2016.

28. Morel J, Casoetto J, Jospé R, Aubert G, Terrana R, Dumont A, et al. De-escalation as part of a global strategy of empiric antibiotic therapy management. A retrospective study in a medico-surgical intensive care unit. Crit Care. 2010 Dec;14(6):R225.

29. Joung KM, Lee JA, Moon SY, Cheong HS, Joo EJ, Ha YE, et al. Impact of de-escalation therapy on clinical outcomes for intensive care unit-acquired pneumonia. Crit Care. 2011;15(2):R79.

30. Gonzalez L, Cravoisy A, Barraud D, Conrad M, Nace L, Lemarié J, et al. Factors influencing the implementation of antibiotic de-escalation and impact of this strategy in critically ill patients. Crit Care 2013, 17(4):R140.

31. Joung KM, Lee JA, Moon SY, Cheong HS, Joo EJ, Ha YE, et al. Impact of de-escalation therapy on clinical outcomes for intensive care unit-acquired pneumonia. Crit Care 2011;15(2):R79.

32. Schluter M, James C, Dominguez A, Tsu L, Seymann G. Practice patterns for antibiotic de-escalation in culture-negative healthcare-associated pneumonia. Infection 2010; 1;38(5):357-62.

33. Zilberberg MD, Shorr AF, Micek ST, Mody SH, Kollef MH. Antimicrobial therapy escalation and hospital mortality among patients with health-care-associated pneumonia: a single-center experience. Chest 2008; 1;134(5):963-8.

34. Shime N, Satake S, Fujita N. De-escalation of antimicrobials in the treatment of bacteraemia due to antibiotic-sensitive pathogens in immunocompetent patients. Infection 2011;39(4):319-25.

35. Chen LF, Vander Weg MW, Hofmann DA, Reisinger HS. The Hawthorne effect in infection prevention and epidemiology. Infect Control Hosp Epidemiol 2015; 36(12): 1444-50.

© Under License of Creative Commons Attribution 3.0 License

Publish in The International Arabic Journal of Antimicrobial Agents

The Journal is an open access peer-reviewed journal that publishes scientific papers about all aspects of antimicrobials. The journal will publish original research articles, reviews, brief reports and case reports dealing with basic and clinical antibacterial agents, antiviral, antiprotozoals, antituberculuous, antifungal and anthelminthes agents. All manuscripts must be prepared in English, and are subject to a rigorous and fair peer-review process. Accepted papers will immediately appear online. The journal aims to advance the knowledge, attitude and the research of chemotherapy in the Arabic world in cooperation with international, national scientific and public societies as well as research centers with similar aims and objectives.